Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Key Inclusion Criteria:

* Metastatic NSCLC with documented EGFR exon 19 deletion or exon 21 (L858R) substitution mutation
* Treatment naive OR one prior standard chemotherapy that is platinum-based
* Adequate organ function defined as follows:

* Hepatic: Total bilirubin \< upper limit of the normal range (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN
* Hematological: absolute neutrophil count (ANC) ≥1500 cells/mm\^3, platelet ≥ 100,000 cells/mm\^3, hemoglobin ≥ 9.0 g/dL
* Renal: Serum creatinine \< ULN OR calculated creatinine clearance (CLcr) of ≥ 60 ml/min
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

Key Exclusion Criteria:

* Known positive status for human immunodeficiency virus (HIV)
* Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C)
* Presence of \> Grade 1 peripheral neuropathy
* Symptomatic leptomeningeal, brain metastases, or spinal cord compression.
* History of interstitial pneumonitis

Note: Other protocol defined Inclusion/Exclusion criteria may apply.